{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T14:24:51Z","timestamp":1794925491041,"version":"4.9.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:00:00Z","timestamp":1718409600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003722"],"award-info":[{"award-number":["82003722"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.biopha.2024.116994","type":"journal-article","created":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T13:26:32Z","timestamp":1718630792000},"page":"116994","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["SGLT2 inhibitor Dapagliflozin alleviates cardiac dysfunction and fibrosis after myocardial infarction by activating PXR and promoting angiogenesis"],"prefix":"10.1016","volume":"177","author":[{"given":"Min","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiameng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiulun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2024.116994_bib1","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.jacc.2021.02.041","article-title":"Long-term outcomes of patients with late presentation of ST-segment elevation myocardial infarction","volume":"77","author":"Cho","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2024.116994_bib2","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jacc.2023.06.024","article-title":"Temporal trends in noncardiovascular morbidity and mortality following acute myocardial infarction","volume":"82","author":"Christensen","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2024.116994_bib3","doi-asserted-by":"crossref","first-page":"5421","DOI":"10.1021\/acsnano.2c10042","article-title":"Cysteine-based redox-responsive nanoparticles for fibroblast-targeted drug delivery in the treatment of myocardial infarction","volume":"17","author":"Ji","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.biopha.2024.116994_bib4","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1161\/CIRCULATIONAHA.119.042157","article-title":"A proposal for modest revision of the definition of type 1 and type 2 myocardial infarction","volume":"140","author":"de Lemos","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2024.116994_bib5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1161\/CIRCRESAHA.116.303577","article-title":"The biological basis for cardiac repair after myocardial infarction: from inflammation to fibrosis","volume":"119","author":"Prabhu","year":"2016","journal-title":"Circ. Res"},{"key":"10.1016\/j.biopha.2024.116994_bib6","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1161\/CIR.0000000000000985","article-title":"Mechanical complications of acute myocardial infarction: a scientific statement from the american heart association","volume":"144","author":"Damluji","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2024.116994_bib7","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1161\/CIRCRESAHA.122.320781","article-title":"Inhibition of fap promotes cardiac repair by stabilizing BNP","volume":"132","author":"Sun","year":"2023","journal-title":"Circ. Res"},{"key":"10.1016\/j.biopha.2024.116994_bib8","article-title":"Injectable hydrogel with MSNs\/microRNA-21-5p delivery enables both immunomodification and enhanced angiogenesis for myocardial infarction therapy in pigs","volume":"7","author":"Li","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.biopha.2024.116994_bib9","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.jacc.2023.01.029","article-title":"Influence of culprit lesion intervention on outcomes in infarct-related cardiogenic shock with cardiac arrest","volume":"81","author":"Zeymer","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2024.116994_bib10","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-022-00925-z","article-title":"Signaling pathways and targeted therapy for myocardial infarction","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.biopha.2024.116994_bib11","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1001\/jama.2022.20149","article-title":"Treatment time and in-hospital mortality among patients with st-segment elevation myocardial infarction, 2018-2021","volume":"328","author":"Jollis","year":"2022","journal-title":"Jama"},{"key":"10.1016\/j.biopha.2024.116994_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110644","article-title":"Glycaemic control in people with diabetes following acute myocardial infarction","volume":"199","author":"Esdaile","year":"2023","journal-title":"Diabetes Res Clin. Pr."},{"key":"10.1016\/j.biopha.2024.116994_bib13","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0140-6736(78)93016-7","article-title":"Blood-sugar and prognosis of myocardial infarction","author":"Burden","year":"1978","journal-title":"Lancet 1"},{"key":"10.1016\/j.biopha.2024.116994_bib14","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0140-6736(99)08415-9","article-title":"Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview","volume":"355","author":"Capes","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2024.116994_bib15","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.2337\/dc18-2356","article-title":"Effects of metformin therapy on coronary endothelial dysfunction in patients with prediabetes with stable angina and nonobstructive coronary artery stenosis: the CODYCE multicenter prospective study","volume":"42","author":"Sardu","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2024.116994_bib16","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s00125-012-2749-0","article-title":"Poor glycaemic control in type 2 diabetes patients reduces endothelial progenitor cell number by influencing SIRT1 signalling via platelet-activating factor receptor activation","volume":"56","author":"Balestrieri","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.biopha.2024.116994_bib17","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.2337\/diabetes.53.9.2383","article-title":"Expression of angiogenic factors during acute coronary syndromes in human type 2 diabetes","volume":"53","author":"Marfella","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2024.116994_bib18","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s40265-019-01148-3","article-title":"Dapagliflozin: a review in type 2 diabetes","volume":"79","author":"Dhillon","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.biopha.2024.116994_bib19","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1007\/s13300-018-0471-8","article-title":"SGLT2 inhibitors in type 2 diabetes management: key evidence and implications for clinical practice","volume":"9","author":"Wilding","year":"2018","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.biopha.2024.116994_bib20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40265-014-0337-y","article-title":"Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus","volume":"75","author":"Scheen","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.biopha.2024.116994_bib21","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2337\/dc10-0612","article-title":"Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"33","author":"Ferrannini","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2024.116994_bib22","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","article-title":"Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Bailey","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2024.116994_bib23","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S2213-8587(21)00243-6","article-title":"Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Jongs","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.biopha.2024.116994_bib24","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/jgs.12881","article-title":"Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension","volume":"62","author":"Leiter","year":"2014","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.biopha.2024.116994_bib25","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.biopha.2024.116994_bib26","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2024.116994_bib27","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1161\/CIRCRESAHA.120.315865","article-title":"S100A9 links inflammation and repair in myocardial infarction","volume":"127","author":"Marinkovi\u0107","year":"2020","journal-title":"Circ. Res"},{"key":"10.1016\/j.biopha.2024.116994_bib28","first-page":"1495","article-title":"Matrix metalloproteinase-2 is activated during ischemia\/reperfusion in a model of myocardial infarction","volume":"29","author":"Cadete","year":"2013","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.biopha.2024.116994_bib29","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"New Engl. J. Med"},{"key":"10.1016\/j.biopha.2024.116994_bib30","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","article-title":"The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial","volume":"27","author":"Nassif","year":"2021","journal-title":"Nat. Med"},{"key":"10.1016\/j.biopha.2024.116994_bib31","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2020.1906","article-title":"Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes","volume":"323","author":"Petrie","year":"2020","journal-title":"Jama"},{"key":"10.1016\/j.biopha.2024.116994_bib32","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/clpt.2008.250","article-title":"Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus","volume":"85","author":"Komoroski","year":"2009","journal-title":"Clin. Pharm. Ther."},{"key":"10.1016\/j.biopha.2024.116994_bib33","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.biopha.2024.116994_bib34","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","article-title":"Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Wheeler","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.biopha.2024.116994_bib35","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1038\/s41591-022-01971-4","article-title":"Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER","volume":"28","author":"Jhund","year":"2022","journal-title":"Nat. Med"},{"key":"10.1016\/j.biopha.2024.116994_bib36","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12933-019-0980-4","article-title":"Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy","volume":"19","author":"Arow","year":"2020","journal-title":"Cardiovasc Diabetol."},{"key":"10.1016\/j.biopha.2024.116994_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2021.109617","article-title":"Dapagliflozin attenuates diabetic cardiomyopathy through erythropoietin up-regulation of AKT\/JAK\/MAPK pathways in streptozotocin-induced diabetic rats","volume":"347","author":"El-Sayed","year":"2021","journal-title":"Chem. Biol. Inter."},{"key":"10.1016\/j.biopha.2024.116994_bib38","doi-asserted-by":"crossref","first-page":"7642","DOI":"10.1111\/jcmm.16601","article-title":"Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPK\u03b1\/TGF-\u03b2\/Smad signalling in type 2 diabetic rats.","volume":"25","author":"Tian","year":"2021","journal-title":"J. Cell Mol. Med"},{"key":"10.1016\/j.biopha.2024.116994_bib39","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.3389\/fphar.2020.01104","article-title":"Dapagliflozin promotes neovascularization by improving paracrine function of skeletal muscle cells in diabetic hindlimb ischemia mice through PHD2\/HIF-1\u03b1 axis","volume":"11","author":"Nugrahaningrum","year":"2020","journal-title":"Front Pharm."},{"key":"10.1016\/j.biopha.2024.116994_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1255904","article-title":"Dapagliflozin promotes angiogenesis in hindlimb ischemia mice by inducing M2 macrophage polarization","volume":"14","author":"Yang","year":"2023","journal-title":"Front Pharm."},{"key":"10.1016\/j.biopha.2024.116994_bib41","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1210\/er.2001-0038","article-title":"The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism","volume":"23","author":"Kliewer","year":"2002","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.biopha.2024.116994_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/biom11081142","article-title":"Pregnane X Receptor (PXR) Polymorphisms and Cancer Treatment","volume":"11","author":"Skandalaki","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.biopha.2024.116994_bib43","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.jfda.2017.11.007","article-title":"PXR as a mediator of herb-drug interaction","volume":"26","author":"Hogle","year":"2018","journal-title":"J. Food Drug Anal."},{"key":"10.1016\/j.biopha.2024.116994_bib44","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00280-014-2494-9","article-title":"Role of pregnane X receptor in chemotherapeutic treatment","volume":"74","author":"Zhuo","year":"2014","journal-title":"Cancer Chemother. Pharm."},{"key":"10.1016\/j.biopha.2024.116994_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.959902","article-title":"The role of pregnane X receptor (PXR) in substance metabolism","volume":"13","author":"Lv","year":"2022","journal-title":"Front Endocrinol. (Lausanne)"},{"key":"10.1016\/j.biopha.2024.116994_bib46","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.4161\/cbt.8.13.8696","article-title":"Regulation of drug resistance by human pregnane X receptor in breast cancer","volume":"8","author":"Chen","year":"2009","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.biopha.2024.116994_bib47","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.2217\/14622416.9.11.1695","article-title":"PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics","volume":"9","author":"Zhang","year":"2008","journal-title":"Pharmacogenomics"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224008783?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224008783?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:27:27Z","timestamp":1782174447000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224008783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":47,"alternative-id":["S0753332224008783"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116994","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SGLT2 inhibitor Dapagliflozin alleviates cardiac dysfunction and fibrosis after myocardial infarction by activating PXR and promoting angiogenesis","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116994","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"116994"}}